Mar 15 |
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
|
Mar 15 |
Madrigal climbs amid hopes for new NASH drug; B. Riley upgrades
|
Mar 15 |
Madrigal, FDA approval in hand, outlines plan to sell MASH drug
|
Mar 14 |
Madrigal Can Market the First Drug for Obesity-Scarred Livers. The Stock Soars.
|
Mar 14 |
Madrigal Stock Soars More Than 20% After FDA Approved First In MASH Treatment
|
Mar 14 |
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
|
Mar 14 |
Madrigal granted FDA approval for NASH therapy
|
Mar 14 |
Madrigal wins FDA approval of first drug for MASH
|
Mar 14 |
Madrigal and liver drug developers fall ahead of FDA decision on NASH therapy
|
Mar 13 |
Liver drug developers outperform as U.S. awaits first NASH drug
|